Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies

References

• Mannaa M, Kramer S, Boschmann M, et al. mTOR and regulation of energy homeostasis in humans. J Mol Med. 2013;91(10):1167–1175.
   PubMed Web of Science ®Google Scholar
• Oddo S. The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed). 2012;4:941–952.
   PubMedGoogle Scholar
• Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem. 2010;10(7):571–581.
   PubMed Web of Science ®Google Scholar
• Zhou HY, Huang SL. Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer. 2012;31(1):8–18.
   PubMed Web of Science ®Google Scholar
• Perluigi M, Di Domenico F, Butterfield DA. mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis. 2015;84:39–49.
   PubMed Web of Science ®Google Scholar
• Kaeberlein M. mTOR inhibition: from aging to autism and beyond. Scientifica. 2013;2013:849186.
   PubMedGoogle Scholar
• Mori S, Nada S, Kimura H, et al. The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase. Plos One. 2014;9(2):e88891.
   PubMed Web of Science ®Google Scholar
• Pei JJ, Hugon J. mTOR-dependent signaling in Alzheimer’s disease. J Cell Mol Med. 2008;12(6B):2525–2532.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Zhang L, et al. Mammalian target of rapamycin: hitting the bull’s-eye for neurological disorders. Oxid Med Cell Longev. 2010;3(6):374–391.
   PubMed Web of Science ®Google Scholar
• Troca-Marin JA, Alves-Sampaio A, Montesinos ML. Deregulated mTOR-mediated translation in intellectual disability. Prog Neurobiol. 2012;96(2):268–282.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Prospective treatment of age-related diseases by slowing down aging. Am J Pathol. 2012;181(4):1142–1146.
   PubMed Web of Science ®Google Scholar
• Di Domenico F, Sultana R, Ferree A, et al. Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease. Antioxid Redox Signal. 2012;17(11):1490–1506.
   PubMed Web of Science ®Google Scholar
• Troca-Marin JA, Casanas JJ, Benito I, et al. The Akt-mTOR pathway in down’s syndrome: the potential use of rapamycin/rapalogs for treating cognitive deficits. CNS Neurol Disord Drug Targets. 2014;13(1):34–40.
   PubMed Web of Science ®Google Scholar
• Tang Z, Bereczki E, Zhang H, et al. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. J Biol Chem. 2013;288(22):15556–15570.
   PubMed Web of Science ®Google Scholar
• Wang C, Yu JT, Miao D, et al. Targeting the mTOR signaling network for Alzheimer’s disease therapy. Mol Neurobiol. 2014;49(1):120–135.
   PubMed Web of Science ®Google Scholar
• Maiese K. Driving neural regeneration through the mammalian target of rapamycin. Neural Regen Res. 2014;9(15):1413–1417.
   PubMed Web of Science ®Google Scholar
• Maiese K. Targeting molecules to medicine with mTOR, autophagy, and neurodegenerative disorders. Br J Clin Pharmacol. 2015. doi:10.1111/bcp.12804. [Epub ahead of print].
   PubMedGoogle Scholar
• Santos RX, Correia SC, Cardoso S, et al. Effects of rapamycin and TOR on aging and memory: implications for Alzheimer’s disease. J Neurochem. 2011;117(6):927–936.
   PubMed Web of Science ®Google Scholar
• Richardson A, Galvan V, Lin AL, et al. How longevity research can lead to therapies for Alzheimer’s disease: the rapamycin story. Exp Gerontol. 2015;68:51–58.
   PubMed Web of Science ®Google Scholar
• Tramutola A, Triplett JC, Di Domenico F, et al. Alteration of mTOR signaling occurs early in the progression of Alzheimer Disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J Neurochem. 2015;133(5):739–749.
   PubMed Web of Science ®Google Scholar
• Tang Z, Ioja E, Bereczki E, et al. mTor mediates tau localization and secretion: implication for Alzheimer’s disease. Biochim Biophys Acta. 2015;1853(7):1646–1657.
   PubMed Web of Science ®Google Scholar
• Zhu XC, Yu JT, Jiang T, et al. Autophagy modulation for Alzheimer’s disease therapy. Mol Neurobiol. 2013;48(3):702–714.
   PubMed Web of Science ®Google Scholar
• Maiese K. Taking aim at Alzheimer’s disease through the mammalian target of rapamycin. Ann Med. 2014;46(8):587–596.
   PubMed Web of Science ®Google Scholar
• Friedman LG, Qureshi YH, Yu WH. Promoting autophagic clearance: viable therapeutic targets in Alzheimer’s disease. Neurotherapeutics. 2015;12(1):94–108.
   PubMed Web of Science ®Google Scholar
• Bedse G, Di Domenico F, Serviddio G, et al. Aberrant insulin signaling in Alzheimer’s disease: current knowledge. Front Neurosci. 2015;9:204.
   PubMed Web of Science ®Google Scholar
• O’ Neill C. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer’s disease. Exp Gerontol. 2013;48(7):647–653.
   PubMed Web of Science ®Google Scholar
• Perluigi M, Pupo G, Tramutola A, et al. Neuropathological role of PI3K/Akt/mTOR axis in down syndrome brain. Biochim Biophys Acta. 2014;1842(7):1144–1153.
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Duan Y, Zheng XF. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today. 2011;16(7–8):325–331.
   PubMed Web of Science ®Google Scholar
• Jung CH, Ro SH, Cao J, et al. mTOR regulation of autophagy. FEBS Lett. 2010;584(7):1287–1295.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.
   PubMed Web of Science ®Google Scholar
• Aylett CH, Sauer E, Imseng S, et al. Architecture of human mTOR complex 1. Science. 2016;351(6268):48–52.
   PubMed Web of Science ®Google Scholar
• Yuan HX, Guan KL. Structural insights of mTOR complex 1. Cell Res. 2016;26(3):267–268.
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484.
   PubMed Web of Science ®Google Scholar
• Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008;27(50):6473–6488.
   PubMed Web of Science ®Google Scholar
• Franke TF. Intracellular signaling by Akt: bound to be specific. Sci Signal. 2008;1(24):pe29.
   PubMed Web of Science ®Google Scholar
• Mi W, Ye Q, Liu S, et al. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Oncotarget. 2015;6(16):13962–13977.
   PubMed Web of Science ®Google Scholar
• Gowans GJ, Hardie DG. AMPK: a cellular energy sensor primarily regulated by AMP. Biochem Soc Trans. 2014;42(1):71–75.
   PubMed Web of Science ®Google Scholar
• Orr ME, Oddo S. Autophagic/lysosomal dysfunction in Alzheimer’s disease. Alzheimers Res Ther. 2013;5(5):53.
   PubMed Web of Science ®Google Scholar
• Takei N, Nawa H. mTOR signaling and its roles in normal and abnormal brain development. Front Mol Neurosci. 2014;7:28.
   PubMed Web of Science ®Google Scholar
• Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signaling networks. Biochem J. 2012;441:1–21.
   PubMed Web of Science ®Google Scholar
• Kim D, Akcakanat A, Singh G, et al. Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors. 2009;27(1):12–21.
   PubMed Web of Science ®Google Scholar
• Khoutorsky A, Bonin RP, Sorge RE, et al. Translational control of nociception via 4E-binding protein 1. Elife. 2015;4:e12002. doi:10.7554/eLife.12002.
   PubMed Web of Science ®Google Scholar
• Tanti JF, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol. 2009;9(6):753–762.
   PubMed Web of Science ®Google Scholar
• Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Current Biol CB. 2004;14(18):1650–1656.
   PubMed Web of Science ®Google Scholar
• Meijer AJ, Lorin S, Blommaart EF, et al. Regulation of autophagy by amino acids and MTOR-dependent signal transduction. Amino Acids. 2015;47:2037–2063.
   PubMed Web of Science ®Google Scholar
• Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, et al. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014;26(12):2694–2701.
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Moroni C, et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10(11):868–880.
   PubMed Web of Science ®Google Scholar
• Seto B. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med. 2012;1(1):29.
   PubMedGoogle Scholar
• Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10(2):159–170.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14):1296–1302.
   PubMed Web of Science ®Google Scholar
• Weichhart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15(10):599–614.
   PubMed Web of Science ®Google Scholar
• Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag. 2007;3(2):191–201.
   PubMedGoogle Scholar
• Chiarini F, Evangelisti C, McCubrey JA, et al. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci. 2015;36(2):124–135.
   PubMed Web of Science ®Google Scholar
• Kwitkowski VE, Prowell TM, Ibrahim A, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist. 2010;15(4):428–435.
   PubMed Web of Science ®Google Scholar
• Yates DH. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus. Expert Rev Resp Med. 2016;10(3):249–260.
   PubMed Web of Science ®Google Scholar
• Peterson ME. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Supportive Care Cancer off J Multinational Assoc. 2013;21(8):2341–2349.
   PubMed Web of Science ®Google Scholar
• Crews L, Spencer B, Desplats P, et al. Selective molecular alterations in the autophagy pathway in patients with lewy body disease and in models of α-synucleinopathy. Plos One. 2010;5(2):e9313.
   PubMed Web of Science ®Google Scholar
• Dancey JE, Monzon J. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Future Oncol. 2011;7(7):827–839.
   PubMed Web of Science ®Google Scholar
• Mita M, Sankhala K, Abdel-Karim I, et al. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs. 2008;17(12):1947–1954.
   PubMed Web of Science ®Google Scholar
• Puranik AS, Dawson ER, Peppas NA. Recent advances in drug eluting stents. Int J Pharm. 2013;441(1–2):665–679.
   PubMed Web of Science ®Google Scholar
• Huang CH, Tsai SJ, Wang YJ, et al. EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol Nutr Food Res. 2009;53(9):1156–1165.
   PubMed Web of Science ®Google Scholar
• Marques FZ, Markus MA, Morris BJ. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell B. 2009;41(11):2125–2128.
   PubMed Web of Science ®Google Scholar
• Beevers CS, Chen L, Liu L, et al. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res. 2009;69(3):1000–1008.
   PubMed Web of Science ®Google Scholar
• Hurez V, Dao V, Liu A, et al. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell. 2015;14(6):945–956.
   PubMed Web of Science ®Google Scholar
• Zaza G, Tomei P, Ria P, et al. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol. 2013;2013:403280.
   PubMedGoogle Scholar
• Sadowski K, Kotulska K, Jozwiak S. Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep PR. 2016;68(3):536–542.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev. 2014;28(3):126–133.
   Web of Science ®Google Scholar
• Alzheimer’s A. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208–245.
   PubMed Web of Science ®Google Scholar
• Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature. 2004;430(7000):631–639.
   PubMed Web of Science ®Google Scholar
• Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med. 2008;14(2):45–53.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–766.
   PubMed Web of Science ®Google Scholar
• Iqbal K, Grundke-Iqbal I. Alzheimer’s disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement. 2010;6(5):420–424.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer’s disease. Brain Res Brain Res Rev. 2005;49(1):1–21.
   PubMedGoogle Scholar
• Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4):329–344.
   PubMed Web of Science ®Google Scholar
• Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem. 2009;110(4):1129–1134.
   PubMed Web of Science ®Google Scholar
• De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev. 2010;90(2):465–494.
   PubMed Web of Science ®Google Scholar
• Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–1159.
   PubMed Web of Science ®Google Scholar
• Oddo S, Vasilevko V, Caccamo A, et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem. 2006;281(51):39413–39423.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259.
   PubMed Web of Science ®Google Scholar
• Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010;13(7):812–818.
   PubMed Web of Science ®Google Scholar
• Contestabile A, Benfenati F, Gasparini L. Communication breaks-down: from neurodevelopment defects to cognitive disabilities in down syndrome. Prog Neurobiol. 2010;91(1):1–22.
   PubMed Web of Science ®Google Scholar
• Cork LC. Neuropathology of down syndrome and Alzheimer disease. Am J Med Genet Suppl. 1990;7:282–286.
   PubMedGoogle Scholar
• Garner CC, Wetmore DZ. Synaptic pathology of down syndrome. Adv Exp Med Biol. 2012;970:451–468.
   PubMed Web of Science ®Google Scholar
• Ling D, Salvaterra PM. A central role for autophagy in Alzheimer-type neurodegeneration. Autophagy. 2009;5(5):738–740.
   PubMed Web of Science ®Google Scholar
• Madeo F, Eisenberg T, Kroemer G. Autophagy for the avoidance of neurodegeneration. Genes Dev. 2009;23(19):2253–2259.
   PubMed Web of Science ®Google Scholar
• An WL, Cowburn RF, Li L, et al. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer’s disease. Am J Pathol. 2003;163(2):591–607.
   PubMed Web of Science ®Google Scholar
• Sun YX, Ji X, Mao X, et al. Differential activation of mTOR complex 1 signaling in human brain with mild to severe Alzheimer’s disease. J Alzheimers Dis. 2014;38(2):437–444.
   PubMed Web of Science ®Google Scholar
• Li X, Alafuzoff I, Soininen H, et al. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer’s disease brain. Febs J. 2005;272(16):4211–4220.
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Moloney A, Kelliher M, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem. 2005;93(1):105–117.
   PubMed Web of Science ®Google Scholar
• Yates SC, Zafar A, Hubbard P, et al. Dysfunction of the mTOR pathway is a risk factor for Alzheimer’s disease. Acta Neuropathol Commun. 2013;1:3.
   PubMedGoogle Scholar
• Lafay-Chebassier C, Paccalin M, Page G, et al. mTOR/p70S6k signaling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer’s disease. J Neurochem. 2005;94(1):215–225.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Magri A, Medina DX, et al. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer’s disease and other tauopathies. Aging Cell. 2013;12(3):370–380.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Majumder S, Richardson A, et al. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem. 2010;285(17):13107–13120.
   PubMed Web of Science ®Google Scholar
• Spilman P, Podlutskaya N, Hart MJ, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer’s disease. PLoS One. 2010;5(4):e9979.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Maldonado MA, Majumder S, et al. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem. 2011;286(11):8924–8932.
   PubMed Web of Science ®Google Scholar
• Majumder S, Richardson A, Strong R, et al. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One. 2011;6(9):e25416.
   PubMed Web of Science ®Google Scholar
• Bhaskar K, Miller M, Chludzinski A, et al. The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol Neurodegener. 2009;4:14.
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhao B, Li K, et al. Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer’s disease? J Neurosci Res. 2012;90(6):1105–1118.
   PubMed Web of Science ®Google Scholar
• Salminen A, Kaarniranta K, Kauppinen A, et al. Impaired autophagy and APP processing in Alzheimer’s disease: the potential role of Beclin 1 interactome. Prog Neurobiol. 2013;106–107:33–54.
   PubMed Web of Science ®Google Scholar
• Martinez-Vicente M. Autophagy in neurodegenerative diseases: from pathogenic dysfunction to therapeutic modulation. Semin Cell Dev Biol. 2015;40:115–126.
   PubMed Web of Science ®Google Scholar
• Halloran J, Hussong SA, Burbank R, et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience. 2012;223:102–113.
   PubMed Web of Science ®Google Scholar
• Pickford F, Masliah E, Britschgi M, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest. 2008;118(6):2190–2199.
   PubMed Web of Science ®Google Scholar
• Rohn TT, Wirawan E, Brown RJ, et al. Depletion of Beclin-1 due to proteolytic cleavage by caspases in the Alzheimer’s disease brain. Neurobiol Dis. 2011;43(1):68–78.
   PubMed Web of Science ®Google Scholar
• O’Neill C, Kiely AP, Coakley MF, et al. Insulin and IGF-1 signaling: longevity, protein homoeostasis and Alzheimer’s disease. Biochem Soc Trans. 2012;40(4):721–727.
   PubMed Web of Science ®Google Scholar
• Gupta A, Dey CS. PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol Biol Cell. 2012;23(19):3882–3898.
   PubMed Web of Science ®Google Scholar
• Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest. 2012;122(4):1339–1353.
   PubMed Web of Science ®Google Scholar
• Ma QL, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci off Soc Neurosci. 2009;29(28):9078–9089.
   PubMed Web of Science ®Google Scholar
• Zhao WQ, De Felice FG, Fernandez S, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. Faseb J. 2008;22(1):246–260.
   PubMed Web of Science ®Google Scholar
• De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA. 2009;106(6):1971–1976.
   PubMed Web of Science ®Google Scholar
• Moloney AM, Griffin RJ, Timmons S, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signaling. Neurobiol Aging. 2010;31(2):224–243.
   PubMed Web of Science ®Google Scholar
• Barone E, Di Domenico F, Cassano T, et al. Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: a new paradigm. Free Radic Biol Med. 2016;91:127–142.
   PubMed Web of Science ®Google Scholar
• Khurana V, Lu Y, Steinhilb ML, et al. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Current Biol CB. 2006;16(3):230–241.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Lee JH, Rubinsztein DC. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol. 2013;105:49–59.
   PubMed Web of Science ®Google Scholar
• Morita T, Sobue K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J Biol Chem. 2009;284(40):27734–27745.
   PubMed Web of Science ®Google Scholar
• Di Domenico F, Coccia R, Cocciolo A, et al. Impairment of proteostasis network in down syndrome prior to the development of Alzheimer’s disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta. 2013;1832(8):1249–1259.
   PubMed Web of Science ®Google Scholar
• Iyer AM, van Scheppingen J, Milenkovic I, et al. mTOR hyperactivation in down syndrome hippocampus appears early during development. J Neuropathol Exp Neurol. 2014;73(7):671–683.
   PubMed Web of Science ®Google Scholar
• Kaeberlein M, Powers RW 3rd, Steffen KK, et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science. 2005;310(5751):1193–1196.
   PubMed Web of Science ®Google Scholar
• Vellai T, Takacs-Vellai K, Zhang Y, et al. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature. 2003;426(6967):620.
   PubMed Web of Science ®Google Scholar
• Kapahi P, Zid BM, Harper T, et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Current Biol CB. 2004;14(10):885–890.
   PubMed Web of Science ®Google Scholar
• Boland B, Kumar A, Lee S, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci off Soc Neurosci. 2008;28(27):6926–6937.
   PubMed Web of Science ®Google Scholar
• Zhang S, Salemi J, Hou H, et al. Rapamycin promotes beta-amyloid production via ADAM-10 inhibition. Biochem Biophys Res Commun. 2010;398(3):337–341.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Majumder S, Deng JJ, et al. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem. 2009;284(40):27416–27424.
   PubMed Web of Science ®Google Scholar
• Tramutola A, Lanzillotta C, Arena A, et al. Increased Mammalian target of rapamycin signaling contributes to the accumulation of protein oxidative damage in a mouse model of down’s syndrome. Neurodegener Dis. 2016;16(1–2):62–68.
   PubMed Web of Science ®Google Scholar
• Lin AL, Zheng W, Halloran JJ, et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s disease. J Cereb Blood Flow Metab off Intsoc. 2013;33(9):1412–1421.
   PubMed Web of Science ®Google Scholar
• Jiang T, Yu JT, Zhu XC, et al. Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer’s disease. Pharmacol Res. 2014;81:54–63.
   PubMed Web of Science ®Google Scholar
• Jiang T, Yu JT, Zhu XC, et al. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. Neuropharmacology. 2014;85:121–130.
   PubMed Web of Science ®Google Scholar
• Orr ME, Salinas A, Buffenstein R, et al. Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer’s disease pathology. Neurobiol Aging. 2014;35(6):1233–1242.
   PubMed Web of Science ®Google Scholar
• Siman R, Cocca R, Dong Y. The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy. PLoS One. 2015;10(11):e0142340.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Di Domenico F, Swomley AM, et al. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in down’s syndrome and Alzheimer’s disease brain. Biochem J. 2014;463(2):177–189.
   PubMed Web of Science ®Google Scholar
• Troca-Marin JA, Alves-Sampaio A, Montesinos ML. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of down’s syndrome. J Neurosci off Soc Neurosci. 2011;31(26):9445–9455.
   PubMed Web of Science ®Google Scholar
• Andrade-Talavera Y, Benito I, Casanas JJ, et al. Rapamycin restores BDNF-LTP and the persistence of long-term memory in a model of down’s syndrome. Neurobiol Dis. 2015;82:516–525.
   PubMed Web of Science ®Google Scholar
• Cheng YF, Guo L, Xie YS, et al. Curcumin rescues aging-related loss of hippocampal synapse input specificity of long term potentiation in mice. Neurochem Res. 2013;38(1):98–107.
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Naiki H, et al. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res. 2004;75(6):742–750.
   PubMed Web of Science ®Google Scholar
• Ringman JM, Frautschy SA, Cole GM, et al. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res. 2005;2(2):131–136.
   PubMedGoogle Scholar
• Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer’s disease: an overview. Ann Indian Acad Neurol. 2008;11(1):13–19.
   PubMed Web of Science ®Google Scholar
• Hamaguchi T, Ono K, Yamada M. Review: Curcumin and Alzheimer’s disease. CNS Neurosci Ther. 2010;16(5):285–297.
   PubMed Web of Science ®Google Scholar
• Goozee KG, Shah TM, Sohrabi HR, et al. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease. Br J Nutr. 2016;115(3):449–465.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang X, Teng Z, et al. Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice. Eur J Pharmacol. 2014;740:312–320.
   PubMed Web of Science ®Google Scholar
• Avrahami L, Farfara D, Shaham-Kol M, et al. Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem. 2013;288(2):1295–1306.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang S, Zhang X, et al. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-beta pathology in a mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2013;10(4):433–441.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Zhang J, Zhu Y, et al. Tripchlorolide improves cognitive deficits by reducing amyloid beta and upregulating synapse-related proteins in a transgenic model of Alzheimer’s disease. J Neurochem. 2015;133(1):38–52.
   PubMed Web of Science ®Google Scholar
• Congdon EE, Wu JW, Myeku N, et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012;8(4):609–622.
   PubMed Web of Science ®Google Scholar
• Caccamo A, De Pinto V, Messina A, et al. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci off Soc Neurosci. 2014;34(23):7988–7998.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Branca C, Talboom JS, et al. Reducing ribosomal protein S6 Kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer’s disease. J Neurosci off Soc Neurosci. 2015;35(41):14042–14056.
   PubMed Web of Science ®Google Scholar
• Chin J. Selecting a mouse model of Alzheimer’s disease. Methods Mol Biol. 2011;670:169–189.
   PubMedGoogle Scholar